Tecovirimat Patent Expiration
Tecovirimat is Used for treating human smallpox disease caused by variola virus in adults and pediatric patients. It was first introduced by Siga Technologies Inc
Tecovirimat Patents
Given below is the list of patents protecting Tecovirimat, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Tpoxx | US11890270 | Polymorphic forms of ST-246 and methods of preparation | Aug 08, 2032 | Siga Technologies |
| Tpoxx | US7737168 | Compounds, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | Sep 04, 2031 | Siga Technologies |
| Tpoxx | US10576165 | ST-246 liquid formulations and methods | Aug 02, 2031 | Siga Technologies |
| Tpoxx | US9233097 | ST-246 liquid formulations | Aug 02, 2031 | Siga Technologies |
| Tpoxx | US9907859 | ST-246 liquid formulations and methods | Aug 02, 2031 | Siga Technologies |
| Tpoxx | US9339466 | Polymorphic forms of ST-246 and methods of preparation | Mar 23, 2031 | Siga Technologies |
| Tpoxx | US8039504 | Chemicals, compositions, and methods for treatment and prevention of orthopoxvirus infections and associated diseases | Jul 23, 2027 | Siga Technologies |
| Tpoxx | US8124643 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun 18, 2024
(Expired) | Siga Technologies |
| Tpoxx | US8530509 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun 18, 2024
(Expired) | Siga Technologies |
| Tpoxx | US8802714 | Compounds, compositions and methods for treatment and prevention of orthopoxvirus infections and associated diseases |
Jun 18, 2024
(Expired) | Siga Technologies |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Tecovirimat's patents.
Latest Legal Activities on Tecovirimat's Patents
Given below is the list recent legal activities going on the following patents of Tecovirimat.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Patent eGrant Notification | 06 Feb, 2024 | US11890270 |
| Mail Patent eGrant Notification | 06 Feb, 2024 | US11890270 |
| Email Notification Critical | 06 Feb, 2024 | US11890270 |
| Recordation of Patent Grant Mailed Critical | 06 Feb, 2024 | US11890270 |
| Recordation of Patent eGrant | 06 Feb, 2024 | US11890270 |
| Patent Issue Date Used in PTA Calculation Critical | 06 Feb, 2024 | US11890270 |
| Email Notification Critical | 18 Jan, 2024 | US11890270 |
| Issue Notification Mailed Critical | 17 Jan, 2024 | US11890270 |
| Application Is Considered Ready for Issue Critical | 21 Dec, 2023 | US11890270 |
| Dispatch to FDC | 21 Dec, 2023 | US11890270 |
Tecovirimat's Family Patents
